TPH2 polymorphisms may modify clinical picture in treatment-resistant depression.
Neurosci Lett
; 464(1): 43-6, 2009 Oct 16.
Article
en En
| MEDLINE
| ID: mdl-19679166
ABSTRACT
The association of two tryptophan hydroxylase 2 (TPH2) polymorphisms and treatment response in electroconvulsive therapy (ECT) and the risk of depression was studied. The patient sample consisted of 119 subjects with treatment-resistant major depressive disorder who were treated with ECT. Treatment response was assessed by the Montgomery and Asberg Depression Rating Scale (MADRS) scores. Patients who had <8 scores in post-treatment MADRS were considered remitters; scores >15 indicated non-response. The polymorphisms studied (rs1386494 and rs1843809) were not associated with treatment response to ECT. However, TPH2 rs1386494 A/A genotype carrying patients had significantly higher MADRS scores before ECT than A/G+G/G genotype carriers (p<0.001). A/A genotype carriers also had a greater decline in MADRS scores than A/G+G/G genotype carriers during the course of ECT treatment (p=0.03). This polymorphism may be associated with the severity of treatment-resistant depression. ECT may able to counteract a putative genetically driven worse depressive phenotype.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Triptófano Hidroxilasa
/
Trastorno Depresivo Mayor
/
Terapia Electroconvulsiva
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Neurosci Lett
Año:
2009
Tipo del documento:
Article
País de afiliación:
Finlandia